Why Gynaecological Cancers Are Some of Pharma’s Most Important Challenges
Gynaecological cancers remain a major pharma challenge. Explore how disease burden, access, tumour biology, and precision medicine are shaping oncology R&D.
Research Informatics
Why Does the True Impact of AI in Drug Discovery Lag?
AI in drug discovery keeps making headlines, but clinical success rates barely move. A new Nature Reviews Perspective explains why, and what pharma should do next.
AI-Driven Digital Organisms Could Change Drug Discovery
AI-driven digital organisms could transform drug discovery by simulating biology across scales. Explore GenBio AI's AIDO vision and the virtual cell.
Better Predictive Modelling for Better Drug Development
Discover how predictive modelling, QSP, AI, and systems biology creates better drug development by connecting biological evidence with better predictions.
BMS and NVIDIA Build Pharma’s AI Supercomputer
BMS and NVIDIA are building a powerful pharma AI factory using advanced supercomputing, AI models, and scientific data to accelerate drug discovery.
Could q-CAR Redefine Drug Discovery?
Find out how q-CAR drug discovery moves beyond static protein structures by linking protein dynamics, ligand activity, and AI to precision drug design.
AI Creates New Viruses? Not Quite. AI-Designed Bacteriophages
AI-designed bacteriophages show how genome models could create new antibacterial therapies while forcing pharma to rethink biological AI governance and biosecurity.
Collaborating for R&D Success in Drug Discovery
Collaboration in drug discovery can shape pharma R&D success. Explore the evidence on pharma partnerships, knowledge sharing, governance, and innovation.
Great Drug Discovery Starts with Great Scientists
Learn how drug discovery scientists are evolving alongside AI, computational biology, and multidisciplinary research to accelerate therapeutic innovation.
Claude Science: An Operating System for AI-Driven Pharma R&D
Claude Science is a new AI R&D tool for drug discovery, integrating 60-plus scientific databases into one place. Here is what pharma R&D teams need to know.
Can Deep Learning Survive the Precision Medicine Paradox?
As precision medicine narrows patient cohorts to rare‑disease scales, deep learning models face a paradox of data scarcity and overfitting that threatens the future of clinical AI.
Genomic Governance Ensures Equity at the Core of Drug Discovery
Discover why genomic equity is essential for reliable AI-driven drug discovery, precision medicine, and building more representative pharmaceutical innovation.
